The Liver Cancer Immune Microenvironment: Emerging Concepts for Myeloid Cell Profiling with Diagnostic and Therapeutic Implications

Konstantinos Arvanitakis^{1

2}, Ioannis Mitroulis³, Antonios Chatzigeorgiou⁴, Ioannis Elefsiniotis⁵, Georgios Germanidis^{1

2}

Affiliations

¹ First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
² Basic and Translational Research Unit (BTRU) of Special Unit for Biomedical Research and Education (BRESU), Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
³ First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
⁴ Department of Physiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁵ University Department of Internal Medicine, General and Oncology Hospital of Kifisia Agioi Anargyroi, 14564 Athens, Greece.

Editorial

Konstantinos Arvanitakis et al. Cancers (Basel). 2023.

. 2023 Feb 28;15(5):1522.

doi: 10.3390/cancers15051522.

Konstantinos Arvanitakis^{1

2}, Ioannis Mitroulis³, Antonios Chatzigeorgiou⁴, Ioannis Elefsiniotis⁵, Georgios Germanidis^{1

2}

¹ First Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
² Basic and Translational Research Unit (BTRU) of Special Unit for Biomedical Research and Education (BRESU), Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.
³ First Department of Internal Medicine, University Hospital of Alexandroupolis, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
⁴ Department of Physiology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
⁵ University Department of Internal Medicine, General and Oncology Hospital of Kifisia Agioi Anargyroi, 14564 Athens, Greece.

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide [...].

All of the authors declare no conflict of interest.

1. Foerster F., Gairing S.J., Ilyas S.I., Galle P.R. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology. 2022;75:1604–1626. doi: 10.1002/hep.32447. - DOI - PMC - PubMed
1. Cheng A.L., Qin S., Ikeda M., Galle P.R., Ducreux M., Kim T.Y., Lim H.Y., Kudo M., Breder V., Merle P., et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 2022;76:862–873. doi: 10.1016/j.jhep.2021.11.030. - DOI - PubMed
1. Anstee Q.M., Reeves H.L., Kotsiliti E., Govaere O., Heikenwalder M. From NASH to HCC: Current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 2019;16:411–428. doi: 10.1038/s41575-019-0145-7. - DOI - PubMed
1. Pfister D., Nunez N.G., Pinyol R., Govaere O., Pinter M., Szydlowska M., Gupta R., Qiu M., Deczkowska A., Weiner A., et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456. doi: 10.1038/s41586-021-03362-0. - DOI - PMC - PubMed
1. Muhammed A., Fulgenzi C.A.M., Dharmapuri S., Pinter M., Balcar L., Scheiner B., Marron T.U., Jun T., Saeed A., Hildebrand H., et al. The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma. Cancers. 2021;14:186. doi: 10.3390/cancers14010186. - DOI - PMC - PubMed